Since BDNF and its TrkB receptors are also involved in the pathogenesis of prostate cancer, clinical research on drugs targeting this pathway and their interference with related carcinogenic effects is ongoing, including Cabozantinib, Larotrctinib, and Entrectinib. Here, BDNF is linked to prostate carcinoma.